Table 3.
Co-antioxidants in stroke and depression from experiments.
| Co-antioxidants in stroke and depression from experiments | ||||
|---|---|---|---|---|
| Antioxidants | Stroke | Depression | ||
| Ischemic stroke | ICH | SAH | ||
| adiponectin | ✔ | ✔ | ||
| ECGG | ✔ | ✔ | ||
| metformin | ✔ | ✔ | ||
| protocatechualdehyde | ✔ | ✔ | ||
| Sirt3 | ✔ | ✔ | ||
| curcumin | ✔ | ✔ | ||
| DHC/A | ✔ | ✔ | ||
| mangiferin | ✔ | ✔ | ||
| progesterone | ✔ | ✔ | ||
| UA | ✔ | ✔ | ||
| dl-3-n-Butylphthalide | ✔ | ✔ | ||
| quercetin | ✔ | ✔ | ||
| resveratrol | ✔ | ✔ | ||
| baicalein | ✔ | ✔ | ||
| allicin | ✔ | ✔ | ||
| melatonin | ✔ | ✔ | ✔ | ✔ |
| Clinical trials and outcomes in stroke | Clinical trials and outcomes in depression | |||
|---|---|---|---|---|
| Types | Outcomes | Types | Outcomes | |
| flavonoid | meta-analysis | high flavonoid reduces risk of stroke | RCT | higher flavonoid links to lower depression risk especially among women |
| UA | RCT and URICOICTUS | UA is safe; UA enhances outcomes of stroke | cohort studies and meta-analysis | UA are associated with low risk of depression hospitalization and lower MDA levels |
| melatonin | RCT | early melatonin usage ameliorates the brain injury of asphyxial newborns | RCT | buspirone-melatonin therapy benefits cognitive function |
| Review | melatonin does not affect mood disorders | |||